Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

EMA’s CHMP Adopts Positive Opinion for AML, Metastatic Melanoma, & Hemophilia A Treatments

By Pharmaceutical Processing | September 25, 2015

​Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an expanded indication of VIDAZA® (azacitidine for injection). VIDAZA is approved for the treatment of acute myeloid leukaemia (AML) in adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT). The expanded indication now covers patients who have >30% myeloblasts, according to the WHO classification. Whereas, previously, the indication covered AML patients with <30% blasts.

Similarly, the EMA’s CHMP has adopted a positive opinion of the Marketing Authorization Application of Exelixis, Inc.‘s cobimetinib. Cobimetinib is a selective MEK inhibitor, used in combination with vemurafenib, for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma. The CHMP’s positive opinion is to be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The European Commission is expected to release its final decision regarding the approval of the combination of cobimetinib and vemurafenib by the end of 2015.

The EMA’s CHMP also bestowed a positive recommendation for the marketing authorization of ELOCTA™ (rFVIIIFc), which was announced by Biogen and Swedish Orphan Biovitrum AB (publ) (Sobi). ELOCTA is a recombinant factor VIII Fc fusion protein product for the treatment of hemophilia A. If approved, it would be the first hemophilia A treatment with prolonged circulation available in the European Union (EU).

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE